10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2026)

10x Genomics has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $10.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 24.12% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.1 million (up 9.87% YoY) and the FY2025 annual result came in at $36.2 million, up 0.89% from the prior year.
• Depreciation & Amortization (CF) retreated to $10.0 million in Q1 2026 per TXG's latest filing, from $10.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $10.3 million in Q3 2025 and troughed at $6.2 million in Q3 2022.
• A 5-year average of $8.4 million and a median of $9.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) jumped 52.94% in 2023, then dropped 12.89% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $6.5 million in 2022, then soared by 49.01% to $9.7 million in 2023, then dropped by 9.95% to $8.8 million in 2024, then rose by 15.03% to $10.1 million in 2025, then declined by 1.07% to $10.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $10.0 million, $10.1 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.